

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

HT-1080

RRID:CVCL_0317

Type: Cell Line

Proper Citation

RRID:CVCL_0317

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0317

Proper Citation: RRID:CVCL_0317

Description: Cell line HT-1080 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Fibrosarcoma

Defining Citation: [PMID:375235](#), [PMID:3335022](#), [PMID:3413074](#), [PMID:3558490](#), [PMID:3986962](#), [PMID:4132053](#), [PMID:6304521](#), [PMID:6538202](#), [PMID:6652615](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:12068308](#), [PMID:17254797](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22282976](#), [PMID:22460905](#), [PMID:24726063](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26351324](#), [PMID:26368816](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT-1080

Synonyms: Ht-1080, HT 1080, HT1080, HT 1080.T

Cross References: BTO:BTO_0001282, CLO:CLO_0004266, CLO:CLO_0004276, EFO:EFO_0002059, MCCL:MCC:0000210, CLDB:cl1735, CLDB:cl1736, CLDB:cl1737, CLDB:cl1738, CLDB:cl1740, CLDB:cl1741, CLDB:cl1742, CLDB:cl4913, ABM:T8971, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-121, ATCC:CRL-7951, BCRC:60037, BCRJ:0110, BioGRID_ORCS_Cell_line:279, BioSample:SAMN01821563, BioSample:SAMN01821634, BioSample:SAMN01821685, BioSample:SAMN01821731, BioSample:SAMN03471913, BioSample:SAMN10987635, cancercellines:CVCL_0317, CCRID:1101HUM-PUMC000070, CCRID:3101HUMTCHu170, CCRID:4201HUM-CCTCC00105, CCTCC:GDC0105, Cell_Model_Passport:SIDM00828, ChEMBL-Cells:ChEMBL3308396, ChEMBL-Targets:ChEMBL614580, CLS:300216, Cosmic:716177, Cosmic:716188, Cosmic:724819, Cosmic:907064, Cosmic:912000, Cosmic:1045409, Cosmic:1067221, Cosmic:1933190, Cosmic:2009505, Cosmic:2301553, Cosmic:2307731, Cosmic:2560245, Cosmic:2764533, Cosmic-CLP:907064, DepMap:ACH-000054, DSMZ:ACC-315, DSMZCellDive:ACC-315, ECACC:85111505, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS039VHD, ENCODE:ENCBS225AAA, ENCODE:ENCBS512AAA, ENCODE:ENCBS513AAA, ENCODE:ENCBS617SGR, ENCODE:ENCBS688VJF, ENCODE:ENCBS798NML, ENCODE:ENCBS816VMN, ENCODE:ENCBS937RAY, FANTOM5_SSTAR:10758-110E2, GDSC:907064, GEO:GSM185089, GEO:GSM185090, GEO:GSM256074, GEO:GSM256075, GEO:GSM256076, GEO:GSM256077, GEO:GSM256078, GEO:GSM256079, GEO:GSM256080, GEO:GSM256081, GEO:GSM256082, GEO:GSM256083, GEO:GSM256084, GEO:GSM256085, GEO:GSM256086, GEO:GSM256087, GEO:GSM256088, GEO:GSM256089, GEO:GSM256090, GEO:GSM256091, GEO:GSM256092, GEO:GSM256093, GEO:GSM256094, GEO:GSM256095, GEO:GSM256096, GEO:GSM256097, GEO:GSM256098, GEO:GSM256099, GEO:GSM256100, GEO:GSM256101, GEO:GSM256102, GEO:GSM256103, GEO:GSM256104, GEO:GSM256105, GEO:GSM256106, GEO:GSM256107, GEO:GSM256108, GEO:GSM256109, GEO:GSM256110, GEO:GSM256111, GEO:GSM256112, GEO:GSM256113, GEO:GSM256114, GEO:GSM827307, GEO:GSM887136, GEO:GSM888207, GEO:GSM1669908, GEO:GSM1676302, GEO:GSM1701637, GEO:GSM3585511, GEO:GSM3585512, GEO:GSM3585513, GEO:GSM3585514, IARC_TP53:21378, IBRC:C10104, ICLC:HTL98016, IGRhCellID:HT1080, IZSLER:BS TCL 27, JCRB:IFO50354, JCRB:JCRB9113, KCB:KCB 2013029YJ, KCLB:10121, LiGeA:CCL_463, LINCS_LDP:LCL-1435, Lonza:744, NCBI_Iran:C437, PharmacDB:HT1080_625_2019, PRIDE:PXD030304, Progenetix:CVCL_0317, PubChem_Cell_line:CVCL_0317, RCB:RCB1956, TKG:TKG 0202, TOKU-E:1963, Wikidata:Q5636047

ID: CVCL_0317

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260905T180809+0000

Ratings and Alerts

No rating or validation information has been found for HT-1080.

Warning: Discontinued: ATCC; CRL-7951

Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: RCB; RCB1956
Caution: This cell line is considered by some researchers to represent a dedifferentiated chondrosarcoma due to the presence of an IDH1 mutation (PubMed=26368816)., Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2382 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Honda R, et al. (2026) The E3 ubiquitin ligase UBR5 promotes ubiquitylation and degradation of the chromatin regulator ATAD2. FEBS letters, 600(9), 1330.

Yang Q, et al. (2026) MSH6 regulates cGAS activity in antiviral and antitumor signaling pathways by governing its cytosolic/nuclear distribution. Cell reports, 45(3), 117059.

Kolak A, et al. (2026) miR-940 suppresses ferroptosis by controlling expression of key regulatory genes. bioRxiv : the preprint server for biology.

Zhou C, et al. (2026) Discovery and Optimization of Novel Carbazole-Based Ferroptosis Inhibitors. Chemistry & biodiversity, 23(6), e71430.

Wolhuter K, et al. (2026) Multi-omic analysis of human PHACTR1 signaling networks. Communications biology, 9(1), 265.

Yang T, et al. (2026) Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(42), e20252.

Dutta S, et al. (2026) MMP9 drives cancer invasion by mediating integrin membrane trafficking and stabilization. *The FEBS journal*.

Zanella E, et al. (2026) Damage-induced i-loops generate eccDNA from repetitive elements. *Molecular cell*, 86(10), 1856.

Yu H, et al. (2026) p300 Degradation by the p53-SIAH1 Axis Relieves TBK1 Acetylation to Enhance Innate Antiviral Immunity. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76101.

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. *Molecular cell*, 86(5), 917.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. *Cell reports*, 45(2), 116970.

Ortega R, et al. (2026) PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs. *Nucleic acids research*, 54(1).

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Caire R, et al. (2026) A 3D morphogenetic blueprint for metastatic outgrowth in breast cancer. *Cell*, 189(12), 3701.

Krumwiede L, et al. (2026) MORC3 represses a tandem repeat enhancer to regulate interferon. *The EMBO journal*, 45(14), 5130.

Yasuda T, et al. (2026) Disrupted mitochondrial dynamics activate RNA-sensing innate immunity through mitochondrial RNA release. *Cell reports*, 45(7), 117607.

Uno S, et al. (2026) Assessment of mitochondrial lipid peroxidation in cells and zebrafish using a targeted mass spectrometry probe. *Cell chemical biology*.

Nebenfuehr B, et al. (2026) Uncovering genetic interactions in the DNA repair network in response to endogenous damage and ionizing radiation. *Cell reports*, 45(1), 116850.

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. *Molecular cancer therapeutics*, 25(3), 457.

Zhang C, et al. (2026) Quantification of Single-Cell Cysteine Using an Electrochemical Nanosensor for Predicting Tumor Disulfidptosis Susceptibility. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(13), e23478.